<span item_type="fundamental" item_id="77f7c7a8e4bfcd64c3adbbc8ec1db4b4" counter_id="ST/US/EVFM" env="prod"></span><span item_type="announcement" item_id="582437765410849025" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 4.952 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.01.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>Net sales for the third quarter of 2025 were $5.0 million, compared to $4.5 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>Operating income for the third quarter of 2025 was $1.0 million, compared to a loss from operations of - $2.4 million in the prior year quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li><li>Total operating expenses decreased to $4.0 million in the third quarter of 2025, versus $6.9 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li><li>Net loss attributable to common stockholders was - $1.7 million in the third quarter of 2025, versus a net loss attributable to common stockholders of - $2.4 million in the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>The company had restricted cash of $0.8 million as of September 30, 2025, compared to $0.7 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li>The company reduced manufacturing costs by approximately 50% for both PHEXXI and SOLOSEC, which is expected to facilitate entry into price-sensitive global markets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li><li>SOLOSEC was submitted for marketing approval in the United Arab Emirates in the third quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>Evofem expects the reduction in COGS to increase per-unit profit and facilitate entry into price-sensitive global markets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li><li>The company anticipates future sales trends to be positively impacted by cost-reduction initiatives and manufacturing efficiencies.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li><li>Evofem is seeking additional financing or other strategic alternatives to fund operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1618835/000149315225022318/ex99-1.htm"></span></li></ul>

Evofem Biosciences | 8-K: FY2025 Q3 Revenue: USD 4.952 M